<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006359</url>
  </required_header>
  <id_info>
    <org_study_id>CALGB-99809</org_study_id>
    <secondary_id>U10CA031946</secondary_id>
    <secondary_id>CALGB-99809</secondary_id>
    <secondary_id>CDR0000068228</secondary_id>
    <nct_id>NCT00006359</nct_id>
  </id_info>
  <brief_title>Androgen Suppression Plus Radiation Therapy in Treating Patients With Prostate Cancer</brief_title>
  <official_title>Phase II Trial of Androgen Suppression for 6 Months Combined With External Beam Radiotherapy (EBRT) With Brachytherapy (BT) Boost for Intermediate Risk Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alliance for Clinical Trials in Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Alliance for Clinical Trials in Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Androgens can cause the growth of prostate cancer cells. Drugs, such as
      leuprolide, goserelin, flutamide, or bicalutamide, may stop the adrenal glands from making
      androgens. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving these
      drugs together with radiation therapy may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well androgen suppression with either leuprolide
      or goserelin and either flutamide or bicalutamide together with radiation therapy works in
      treating patients with prostate cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the feasibility of androgen-suppression therapy combined with external-beam
           radiotherapy and boost brachytherapy (EBRT+BT) in patients with intermediate-risk
           localized prostate cancer.

        -  Determine the safety of EBRT+BT in these patients.

        -  Determine, in a preliminary manner, the efficacy of EBRT+BT in terms of rate of local
           recurrence at 5 years, time to prostate-specific antigen failure, and time to first
           rectal/bladder injury, in these patients.

      OUTLINE: Patients receive either leuprolide intramuscularly or goserelin subcutaneously once
      every 12 weeks for a total of 24 weeks. Patients also receive either oral flutamide three
      times daily or oral bicalutamide once daily for 4 weeks.

      Within 4 weeks after initiation of androgen-suppression therapy, patients undergo
      external-beam radiotherapy (EBRT) once daily, 5 days a week, for 5 weeks. At 2-4 weeks after
      completion of EBRT, patients undergo transrectal ultrasound-guided boost brachytherapy with
      implanted iodine I 125 or palladium Pd 103 seeds.

      Patients are followed every 3 months for 2 years and then every 6 months for 4 years.

      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2000</start_date>
  <completion_date type="Actual">March 2012</completion_date>
  <primary_completion_date type="Actual">October 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Toxicity</measure>
    <time_frame>q 3 mon for 2 yrs post tx initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to PSA failure</measure>
    <time_frame>6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>6 years</time_frame>
    <description>Progression free and overall survival will be assessed</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">63</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Androgen suppression + EBRT + Brachytherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Androgen suppression with external beam radiation therapy followed by brachytherapy boost</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LHRH agonist</intervention_name>
    <description>Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2</description>
    <arm_group_label>Androgen suppression + EBRT + Brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>antiandrogen</intervention_name>
    <description>flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks</description>
    <arm_group_label>Androgen suppression + EBRT + Brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radiation therapy</intervention_name>
    <description>4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)</description>
    <arm_group_label>Androgen suppression + EBRT + Brachytherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Brachytherapy boost</intervention_name>
    <description>Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy</description>
    <arm_group_label>Androgen suppression + EBRT + Brachytherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the prostate

               -  Must have one of the following prognostic factors:

                    -  Stage T1-2, N0; prostate-specific antigen (PSA) ≤ 10 ng/mL; and Gleason
                       score &gt; 6

                    -  Stage T1-2, N0; PSA &gt; 10 ng/mL and &lt; 20 ng/mL; and Gleason score ≤ 6

                    -  Stage T3a, N0; PSA ≤ 10 ng/mL; and Gleason score ≤ 6

          -  Prostate volume &lt; 60 cc by transrectal ultrasound

          -  No distant or nodal metastases

               -  No metastatic disease by bone scan, CT scan, or MRI

        PATIENT CHARACTERISTICS:

        Age:

          -  18 and over

        Performance status:

          -  ECOG 0-2

        Life expectancy:

          -  Not specified

        Hematopoietic:

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

        Hepatic:

          -  Bilirubin ≤ 1.5 times upper limit of normal

        Renal:

          -  Not specified

        Other:

          -  Fertile patients must use effective contraception

        PRIOR CONCURRENT THERAPY:

        Biologic therapy:

          -  No prior immunotherapy for prostate cancer

        Chemotherapy:

          -  No prior chemotherapy for prostate cancer

        Endocrine therapy:

          -  Prior androgen-suppression therapy for up to 4 weeks duration allowed if initiated
             within 4 weeks of study radiotherapy

          -  No other prior hormonal therapy

        Radiotherapy:

          -  No prior radiotherapy for prostate cancer

        Surgery:

          -  No prior surgery for prostate cancer

          -  No prior transurethral resection of the prostate

        Other:

          -  No prior alternative therapy (e.g., PC-SPES) for prostate cancer
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Hurwitz, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Dana-Farber/Brigham and Women's Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beebe Medical Center</name>
      <address>
        <city>Lewes</city>
        <state>Delaware</state>
        <zip>19958</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Christiana Care Health Services</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Francis Hospital</name>
      <address>
        <city>Wilmington</city>
        <state>Delaware</state>
        <zip>19805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Hospital Cancer Institute at Florida Hospital Orlando</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Union Hospital Cancer Center at Union Hospital</name>
      <address>
        <city>Elkton MD</city>
        <state>Maryland</state>
        <zip>21921</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hudner Oncology Center at Saint Anne's Hospital</name>
      <address>
        <city>Fall River</city>
        <state>Massachusetts</state>
        <zip>02721</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMASS Memorial Cancer Center - University Campus</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ellis Fischel Cancer Center at University of Missouri - Columbia</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arch Medical Services, Incoroporated at Center for Cancer Care Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Cancer Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washoe Cancer Services at Washoe Medical Center - Reno</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCOP - Syracuse Hematology-Oncology Associates of Central New York, P.C.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University Hospital</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veterans Affairs Medical Center - Syracuse</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community General Hospital of Greater Syracuse</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Cancer Center at Presbyterian Hospital</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne Memorial Hospital, Incorporated</name>
      <address>
        <city>Goldsboro</city>
        <state>North Carolina</state>
        <zip>27534</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zimmer Cancer Center at New Hanover Regional Medical Center</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Center at Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Danville Regional Medical Center</name>
      <address>
        <city>Danville</city>
        <state>Virginia</state>
        <zip>24541</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Hurwitz MD, Halabi S, Archer L, McGinnis LS, Kuettel MR, DiBiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen deprivation for treatment of intermediate-risk prostate cancer: long-term results of CALGB 99809. Cancer. 2011 Dec 15;117(24):5579-88. doi: 10.1002/cncr.26203. Epub 2011 Jul 25.</citation>
    <PMID>22535500</PMID>
  </results_reference>
  <results_reference>
    <citation>Hurwitz MD, Halabi S, Ou SS, McGinnis LS, Keuttel MR, Dibiase SJ, Small EJ. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809. Int J Radiat Oncol Biol Phys. 2008 Nov 1;72(3):814-9. doi: 10.1016/j.ijrobp.2008.01.010. Epub 2008 Apr 11.</citation>
    <PMID>18407435</PMID>
  </results_reference>
  <results_reference>
    <citation>Hurwitz MD, Halabi S, Ou SS, et al.: Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate risk prostate cancer: an initial report of CALGB 99-809. [Abstract] Int J Radiat Oncol Biol Phys 66 (3 Suppl 1): A-2230, S337-8, 2006.</citation>
  </results_reference>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 4, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>July 15, 2016</last_update_submitted>
  <last_update_submitted_qc>July 15, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 18, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>adenocarcinoma of the prostate</keyword>
  <keyword>stage I prostate cancer</keyword>
  <keyword>stage II prostate cancer</keyword>
  <keyword>stage III prostate cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
    <mesh_term>Androgen Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

